{"id":"NCT02300233","sponsor":"Ionis Pharmaceuticals, Inc.","briefTitle":"The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia","officialTitle":"The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-05","primaryCompletion":"2016-07-27","completion":"2017-01-24","firstPosted":"2014-11-24","resultsPosted":"2022-04-13","lastUpdate":"2022-04-13"},"enrollment":114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertriglyceridemia"],"interventions":[{"type":"DRUG","name":"Volanesorsen","otherNames":["ISIS 304801"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Volanesorsen 300 mg weekly","type":"EXPERIMENTAL"},{"label":"Volanesorsen 300 mg biweekly, post Week 13","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 26 weeks in participants with Hypertriglyceridemia.","primaryOutcome":{"measure":"Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3","timeFrame":"Baseline to 3 months","effectByArm":[{"arm":"Placebo","deltaMin":-0.9,"sd":null},{"arm":"Volanesorsen Total","deltaMin":-71.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Canada","France","Germany","Netherlands","United Kingdom"]},"refs":{"pmids":["37164837","33798466"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":38},"commonTop":["Injection site erythema","Injection site pain","Injection site swelling","Injection site pruritus","Injection site discolouration"]}}